ArticleDrug delivery2017
Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer.
Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation.Journal of nanobiotechnology · 2026Review
- Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer.Oncology research · 2026Review
- An acid-responsive bone-targeting nanoplatform loaded with curcumin balances osteogenic and osteoclastic functions.Regenerative biomaterials · 2025Article
- Nanomaterial-assisted theranosis of bone diseases.Bioactive materials · 2023Review
- Biomedical applications of solid-binding peptides and proteins.Materials today. Bio · 2023Review
- Review
- Lipid-Based Nano-Sized Cargos as a Promising Strategy in Bone Complications: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- Advances in lipid-based nanocarriers for breast cancer metastasis treatment.Frontiers in medical technology · 2022Review
- The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials.Drug delivery · 2021Review
- Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment.ACS pharmacology & translational science · 2021Review
- One-Step Microfluidic Fabrication of Multi-Responsive Liposomes for Targeted Delivery of Doxorubicin Synergism with Photothermal Effect.International journal of nanomedicine · 2021Article
- Review
- Bone Diseases: Current Approach and Future Perspectives in Drug Delivery Systems for Bone Targeted Therapeutics.Nanomaterials (Basel, Switzerland) · 2020Review
- Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery.Advanced therapeutics · 2019Article
- Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.International journal of molecular sciences · 2018Review
- Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts.International journal of nanomedicine · 2018Article
- Perfluorooctylbromide nanoparticles for ultrasound imaging and drug delivery.International journal of nanomedicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer frequently metastasizes to bone, where it leads to poor clinical prognosis. Due to the peculiarity of the bone microstructure, the uptake of drugs often happens at non-targeted sites, which produces a similar cytotoxicity in both cancerous and healthy cells. In this study, a rational strategy was implemented to take advantage of a combination of both an octapeptide with eight repeating sequences of aspartate (Asp
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.